Tristel, the provider of infection control and hygiene products, reported an increase in turnover and profit for the fifth consecutive year since joining AIM. Turnover increased by 28% to £8.67m (2009: £6.85m) and profit before tax was up by 34.2% to £1.72m (2009: £1.29 million), including an exceptional credit of £233,000 (2009: nil). The increase in turnover was primarily attributable to the company's acquisition of the MediChem animal healthcare manufacturing rights in 2009, which contributed £1.6 million. International sales grew by 59% (albeit from a small base) to about £0.75 million. Overall organic growth of the company’s proprietary chlorine dioxide products for the hospital environment was more modest at c. 4%.
Also noteworthy is the company's planned foray into sterile disinfectant products, intended for use in pharmaceutical production facilities and hospital pharmacies where a sterile "clean room" environment must be maintained.
LCF Research will be speaking to Paul Swinney and Elizabeth Dixon of Tristel Plc on Tuesday 19th October at 12.30 pm. The discussion will focus on the company’s preliminary results (mentioned above), business expansion plans and will be followed by a brief Q&A session.
If you would like to join the web conference, please email info@lcfresearch.com to confirm your participation. The web conference and Q&A will also be recorded and posted on Tristel’s profile page on the LCF Research website.
About the Author
LCF Research
0 comments
